Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
Yazan F Madanat,1 Mitchell R Smith,2 Alexandru Almasan,3 Brian T Hill2 1Department of Internal Medicine, 2Department of Hematology and Medical Oncology, Taussig Cancer Institute, 3Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA Abstract: Chronic lymphoc...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-03-01
|
| Series: | Blood and Lymphatic Cancer: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/idelalisib-therapy-of-indolent-b-cell-malignancies-chronic-lymphocytic-peer-reviewed-article-BLCTT |
| _version_ | 1818424543548538880 |
|---|---|
| author | Madanat YF Smith MR Almasan A Hill BT |
| author_facet | Madanat YF Smith MR Almasan A Hill BT |
| author_sort | Madanat YF |
| collection | DOAJ |
| description | Yazan F Madanat,1 Mitchell R Smith,2 Alexandru Almasan,3 Brian T Hill2 1Department of Internal Medicine, 2Department of Hematology and Medical Oncology, Taussig Cancer Institute, 3Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA Abstract: Chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma are indolent B-cell lymphoproliferative disorders that mainly affect an older population. Although the majority of patients in need of treatment derive significant benefit from conventional chemotherapeutic agents as well as monoclonal antibodies, less toxic and more effective treatments are needed. Novel agents that inhibit the B-cell receptor signaling pathway have shown promising outcomes in these disorders. Idelalisib is a potent selective oral inhibitor of phosphatidylinositol 3-kinase delta and has shown significant clinical activity in B-cell malignancies. In this review, we summarize the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of relapsed/refractory disease. The adverse effect profile includes autoimmune disorders such as transaminitis, colitis, and pneumonitis. Given the efficacy and manageable toxicity profile of idelalisib, it is being increasingly incorporated into the management of indolent B-cell malignancies. Keywords: idelalisib, PI3Kδ inhibitors, chronic lymphocytic leukemia, follicular lymphoma |
| first_indexed | 2024-12-14T13:59:43Z |
| format | Article |
| id | doaj.art-89d8c5e4fe2c4f3693441581fda438cc |
| institution | Directory Open Access Journal |
| issn | 1179-9889 |
| language | English |
| last_indexed | 2024-12-14T13:59:43Z |
| publishDate | 2016-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Blood and Lymphatic Cancer: Targets and Therapy |
| spelling | doaj.art-89d8c5e4fe2c4f3693441581fda438cc2022-12-21T22:58:45ZengDove Medical PressBlood and Lymphatic Cancer: Targets and Therapy1179-98892016-03-012016Issue 11625994Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomasMadanat YFSmith MRAlmasan AHill BTYazan F Madanat,1 Mitchell R Smith,2 Alexandru Almasan,3 Brian T Hill2 1Department of Internal Medicine, 2Department of Hematology and Medical Oncology, Taussig Cancer Institute, 3Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA Abstract: Chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma are indolent B-cell lymphoproliferative disorders that mainly affect an older population. Although the majority of patients in need of treatment derive significant benefit from conventional chemotherapeutic agents as well as monoclonal antibodies, less toxic and more effective treatments are needed. Novel agents that inhibit the B-cell receptor signaling pathway have shown promising outcomes in these disorders. Idelalisib is a potent selective oral inhibitor of phosphatidylinositol 3-kinase delta and has shown significant clinical activity in B-cell malignancies. In this review, we summarize the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of relapsed/refractory disease. The adverse effect profile includes autoimmune disorders such as transaminitis, colitis, and pneumonitis. Given the efficacy and manageable toxicity profile of idelalisib, it is being increasingly incorporated into the management of indolent B-cell malignancies. Keywords: idelalisib, PI3Kδ inhibitors, chronic lymphocytic leukemia, follicular lymphomahttps://www.dovepress.com/idelalisib-therapy-of-indolent-b-cell-malignancies-chronic-lymphocytic-peer-reviewed-article-BLCTTIdelalisibPI3Kδ inhibitorschronic lymphocytic leukemiafollicular lymphoma |
| spellingShingle | Madanat YF Smith MR Almasan A Hill BT Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas Blood and Lymphatic Cancer: Targets and Therapy Idelalisib PI3Kδ inhibitors chronic lymphocytic leukemia follicular lymphoma |
| title | Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas |
| title_full | Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas |
| title_fullStr | Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas |
| title_full_unstemmed | Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas |
| title_short | Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas |
| title_sort | idelalisib therapy of indolent b cell malignancies chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas |
| topic | Idelalisib PI3Kδ inhibitors chronic lymphocytic leukemia follicular lymphoma |
| url | https://www.dovepress.com/idelalisib-therapy-of-indolent-b-cell-malignancies-chronic-lymphocytic-peer-reviewed-article-BLCTT |
| work_keys_str_mv | AT madanatyf idelalisibtherapyofindolentbcellmalignancieschroniclymphocyticleukemiaandsmalllymphocyticorfollicularlymphomas AT smithmr idelalisibtherapyofindolentbcellmalignancieschroniclymphocyticleukemiaandsmalllymphocyticorfollicularlymphomas AT almasana idelalisibtherapyofindolentbcellmalignancieschroniclymphocyticleukemiaandsmalllymphocyticorfollicularlymphomas AT hillbt idelalisibtherapyofindolentbcellmalignancieschroniclymphocyticleukemiaandsmalllymphocyticorfollicularlymphomas |